CAPLIPOINT · Health Care · 2026-08-07

Caplin Point Laboratories Ltd

5.4★ FairSolid +6.1Stage 2 · wk 8In scan: Breakout WatchMARKET: BULL TOPPING · 2026-08-07
₹2,574.1
-0.45% today
₹19,566 Cr · Mid cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.

Visit company website →
P/E (TTM)
24.1
Forward 18.9
Earnings Growth (YoY)
+19.4%
Revenue +19.0%
ROE
+19.9%
Profit margin +29.3%
Dividend Yield
0.39%
P/B 4.4
vs 52W High
-3.6%
₹1,504.8 lo₹2,671.5 hi
3.6% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 8
1w13w26w
Week 8 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
29.7%
200 DMA: ₹1,984 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.28x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
→
MA20 flat · -0.1% vs MA50 +12.2%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
This stock ranks #31 of 79 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Ranks #23 of 53 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-15 → 2026-08-07
S2 40w
S2 34w
S4 24w
2023-05-152026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 1w → S1 4w → S2 40w → S3 12w → S2 34w → S3 9w → S4 5w → S1 7w → S2 4w → S1 1w → S4 3w → S1 1w → S2 6w → S3 5w → S4 24w → S1 5w → S2 8w current
Total tracked: 167 weeks across 17 stage runs.
1M
-1.8%
3M
+38.7%
6M
+43.0%
YTD
+35.9%
1Y
+20.1%
Scan Membership
Breakout Watch
Latest: 2026-06-16
4 appearances in last 60 days. First seen: 2024-06-19.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S2
Wk 8 · Vol —x
2026-08-06S2
Wk 8 · Vol —x
2026-08-05S2
Wk 8 · Vol —x
2026-08-04S2
Wk 7 · Vol —x
2026-08-03S2
Wk 7 · Vol —x
2026-07-31S2
Wk 7 · Vol —x
2026-07-30S2
Wk 7 · Vol —x
2026-07-29S2
Wk 7 · Vol —x
2026-07-28S2
Wk 6 · Vol —x
2026-07-27S2
Wk 6 · Vol —x
2026-07-24S2
Wk 6 · Vol —x
2026-07-23S2
Wk 6 · Vol —x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹2,456.2
200 DMA
₹1,984
52W High
₹2,671.5
52W Low
₹1,504.8
5D Low
₹2,541.8
Resistance levels (recent highs)
20d High
₹2,671.5
60d High
₹2,671.5
120d High
₹2,671.5
250d High
₹2,671.5
Next resistance
+3.8%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.